Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910152 · ClinicalTrials.gov registry record · Phase 1
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
A Phase 1 study, sponsored by Hannah Choe, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04910152 is a Phase 1 study that was terminated before completion, run by Hannah Choe, MD. The registered enrollment target is 2 participants.
The verdict
NCT04910152, a Phase 1 study, was terminated before completion, sponsored by Hannah Choe, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side effect profile. PLX51107 may work better in treating steroid-refractory acute GVHD.
Interventions
- DRUG BRD4 Inhibitor PLX51107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04910152
The ClinicalTrials.gov registry entry for NCT04910152 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hannah Choe, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BRD4 Inhibitor PLX51107 is the first listed.
NCT04910152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04910152 about?
NCT04910152 is a clinical study titled "Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD". This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side...
What is the current status of trial NCT04910152?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-04-19. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT04910152?
The interventions under investigation include: BRD4 Inhibitor PLX51107 (DRUG).
Who is sponsoring clinical trial NCT04910152?
This trial is sponsored by Hannah Choe, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.